Has Keaton Nasser, MD received payments from drug or device companies?

Yes. Drug and device makers reported $41,356 in general payments to Keaton Nasser, MD across 321 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Keaton Nasser, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Keaton Nasser, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Keaton Nasser, MD

Interventional Cardiology · Clackamas, ORNPI 1720433683

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (48.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Boston Scientific at 53.6% of the total. Reporting peaked in 2023 at $27,215 and has fallen 91.3% since, to $2,373 in 2025.

$41,356in general payments, 2019–2025

Across 321 payments — averaging $128.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$22K
Edwards Lifesciences$10K
Abbott$3K
Medtronic$2K
Abiomed$945
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$905
plus $2K from 14 others

What the payments were for

Grants$20,00048%
Travel & lodging$8,40320%
Food & beverage$11,82029%
Education$1,0573%
Gifts$750%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	30	$22,152
Edwards Lifesciences	180	$10,199
Abbott	39	$3,045
Medtronic(2 entities)	26	$2,386
Abiomed	8	$945
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	11	$905
Shockwave Medical, Inc	2	$243
Cvrx, Inc.	2	$232
Johnson & Johnson	2	$207
AstraZeneca	3	$182
Kestra Medical Technology Services, Inc.	3	$166
Esperion Therapeutics, Inc.	2	$165
Cardiovascular Systems Inc.	2	$161
Chiesi USA, Inc.	2	$94
Merck	1	$73
Cardiva Medical, Inc.	3	$68
Cathworks, Inc.	1	$45
Lantheus Medical Imaging, Inc.	2	$35
Philips North America LLC	1	$30
E.r. Squibb & Sons, L.L.C.	1	$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Edwards SAPIEN 3 Transcatheter Heart Valve$2,600
PASCAL$2,088
COREVALVE EVOLUT R$1,418
MitraClip$1,089
WATCHMAN Access System$953
Impella$885
Ensite Cardiac Mapping System$460
LifeVest$420
WATCHMAN FLX$417
ENSITE$263
Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$243
Barostim Neo System$232
CoreValve Evolut$165
Diamondback Coronary$148
VersaCross Access Solution$147
3F$137
NEXLIZET$122
NEXLETOL$122
Assure WCD$116
XARELTO$110

How this compares

$41,356 in reported general payments places this provider in the 85th percentile of 68 interventional cardiology providers in Oregon.

See all interventional cardiology providers in Oregon →

Medicare billing

Part B allowed, 2024

$3,599

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ClopidogrelClopidogrel Bisulfate	15	$146

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Clackamas

Abhimanyu UberoiClackamas$41K
Ross VimrClackamas$11K
Jason WollmuthPortland$749K
Saurabh GuptaBend$550K
Ethan KorngoldPortland$407K
Amish DesaiPortland$186K
Harsh GolwalaPortland$105K
Brandon JonesPortland$101K
Sudeshna BanerjeeSpringfield$66K
Kathryn DawsonPortland$57K

See the full list for Oregon →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →